Nimodipine
Nimodipine: The Premium Calcium Channel Blocker for Improved Neurological Health
Nimodipine is a specialized calcium channel blocker clinically proven to improve outcomes after subarachnoid hemorrhage (SAH). As a selective cerebral vasodilator, Nimodipine helps prevent cerebral vasospasm and subsequent ischemia following aneurysmal bleeding.
Key Benefits of Nimodipine
- Reduces incidence of severe neurological deficits by 34%
- Decreases mortality rates by 40% in SAH patients
- Improves cerebral blood flow without significant systemic effects
- Available in multiple convenient dosage forms
Nimodipine Technical Specifications
| Parameter | Value |
|---|---|
| Chemical Name | 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl ester |
| Molecular Formula | C21H26N2O7 |
| Molecular Weight | 418.45 g/mol |
| Solubility | Practically insoluble in water, freely soluble in ethanol and methanol |
| Melting Point | 124-128°C |
| Storage Conditions | Store below 25°C in original packaging |
Available Formulations
| Form | Strength | Pack Size |
|---|---|---|
| Oral Solution | 30mg/50mL | 10 bottles per carton |
| Tablets | 30mg | 100 tablets per bottle |
| Injection | 10mg/50mL | 10 vials per carton |
Nimodipine FAQ Section
Q: How does Nimodipine work in treating subarachnoid hemorrhage?
A: Nimodipine selectively blocks calcium channels in cerebral arteries, preventing calcium influx that causes vasospasm. By dilating these vessels, it maintains adequate blood flow to vulnerable brain areas during the critical 21-day period post-hemorrhage.
Q: What is the standard dosing protocol for Nimodipine?
A: For SAH treatment, the standard regimen is 60mg every 4 hours (360mg daily) for 21 consecutive days. Therapy should begin within 96 hours of hemorrhage, starting with IV administration if swallowing is impaired before transitioning to oral forms.
Q: Are there any food interactions with Nimodipine?
A: Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 metabolism, potentially increasing Nimodipine plasma concentrations by 50-100%. Regular meals don't affect absorption, but high-fat meals may delay peak concentration by 1 hour.
Pharmacokinetic Profile
| Parameter | Value |
|---|---|
| Bioavailability | 13% (oral solution), 5-10% (tablets) |
| Protein Binding | >95% |
| Peak Plasma Time | 1 hour (oral solution), 0.5-1.5 hours (tablets) |
| Half-Life | 8-9 hours |
| Metabolism | Hepatic (CYP3A4-mediated) |
| Excretion | 50% urine, 32% feces |
Clinical Advantages of Nimodipine
- Unique selectivity for cerebral vasculature minimizes peripheral effects
- Lipophilic nature allows excellent blood-brain barrier penetration
- Proven neuroprotective effects beyond vascular actions
- Established safety profile with decades of clinical use
Additional Nimodipine FAQs
Q: Can Nimodipine be used for other neurological conditions?
A: While primarily indicated for SAH, some studies investigate Nimodipine for vascular dementia, migraine prophylaxis, and traumatic brain injury due to its neuroprotective properties. However, these uses remain off-label without definitive clinical evidence.
Q: What monitoring is required during Nimodipine therapy?
A: Regular blood pressure monitoring is essential (risk reduction of 20-25 mmHg systolic). Liver function tests should be performed in prolonged therapy. Neurological status must be assessed frequently for treatment efficacy evaluation.
Q: How should Nimodipine be discontinued?
A: The full 21-day course should be completed without interruption. If discontinuation is medically necessary, taper gradually over 2-3 days while monitoring for rebound vasospasm symptoms.
Drug Interaction Profile
| Concomitant Drug | Interaction Effect | Management |
|---|---|---|
| CYP3A4 inhibitors (ketoconazole, erythromycin) | Increased Nimodipine levels | Monitor for hypotension, reduce Nimodipine dose if needed |
| CYP3A4 inducers (rifampin, phenytoin) | Decreased Nimodipine efficacy | Consider dose increase or alternative therapy |
| Other antihypertensives | Additive hypotensive effect | Close BP monitoring, adjust doses accordingly |
| Beta-blockers | Potential myocardial depression | Use with extreme caution in heart failure patients |
Nimodipine remains the gold standard pharmacological intervention for preventing ischemic neurological deficits following aneurysmal subarachnoid hemorrhage. Its unique pharmacological profile offers targeted cerebral protection with manageable side effects when administered according to established protocols.